Skip to main content
SpringerLink
Log in

Antithrombotika und Antihämorrhagika

  • Chapter
Arzneiverordnungs-Report 2011

Zusammenfassung

Antithrombotika (Antikoagulantien, Thrombozytenaggregationshemmer) werden bei Thrombosen, Embolien und arteriellen Gefäßkrankheiten mit unterschiedlichen therapeutischen Schwerpunkten eingesetzt. Die akute Antikoagulation mit Heparin und die nachfolgende Gabe oraler Vitamin-K-Antagonisten ist die Standardtherapie für akute Venenthrombosen und Lungenembolien. Daneben werden Vitamin-K-Antagonisten zur Prophylaxe kardiogener Hirnembolien bei atrialen Thromben und bei arteriosklerotisch bedingten Karotisstenosen angewendet.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Algra A, de Schryver EL, van Gijn J, Kappelle LJ, Koudstaal PJ (2001): Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin. Cochrane Database Syst Rev 2001 (4): CD001342.

    Google Scholar 

  • Antithrombotic Trialists’ Collaboration (2002): Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Brit Med J 324: 71–86.

    Article  Google Scholar 

  • Bhatt DL, Fox KAA, Hacke W, Berger PB, Black HR et al. (2006): Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med. 354: 1706–1717.

    Article  PubMed  CAS  Google Scholar 

  • Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Scirica BM, Murphy SA, Cannon CP, COGENT Investigators (2010): Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 363: 1909–1917.

    Article  PubMed  CAS  Google Scholar 

  • Born GVR, Collins R (1997): Aspirin versus clopidogrel: the wrong question? Lancet 349: 806–807.

    Article  PubMed  CAS  Google Scholar 

  • Bowry ADK, Brookhart MA, Choudhry NK (2008): Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared with antiplatelet monotherapy for the prevention of vascular events. Am J Cardiol 101: 960–966.

    Article  PubMed  CAS  Google Scholar 

  • CAPRIE Steering Committee (1996): A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348: 1329–1339.

    Article  Google Scholar 

  • Chan FK, Ching JY, Hung LC, Wong VW, Leung VK, Kung NN, Hui AJ, Wu JC, Leung WK, Lee VW, Lee KK, Lee YT, Lau JY, To KF, Chan HL, Chung SC, Sung JJ (2005): Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 352: 238–244.

    Article  PubMed  CAS  Google Scholar 

  • Collet JP, Hulot JS, Pena A et al. (2009): Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373: 309–317.

    Article  PubMed  CAS  Google Scholar 

  • De Schryver ELLM, Algra A, van Gijn MD (2003): Cochrane Review: Dipyridamole for preventing major vascular events in patients with vascular disease. Stroke 34: 2072–2080.

    Article  PubMed  Google Scholar 

  • Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ; MATCH investigators (2004): Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364: 331–337.

    Article  PubMed  CAS  Google Scholar 

  • Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A (1996): European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143: 1–13.

    Article  PubMed  CAS  Google Scholar 

  • Eikelboom JW, Anand SS, Maimberg K, Weitz JI, Ginsberg JS, Yusuf S (2000): Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 355: 1936–1942.

    Article  PubMed  CAS  Google Scholar 

  • Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S (2003): Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105: 1650–1655.

    Article  Google Scholar 

  • Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W, RECORD1 Study Group (2008): Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 358: 2765–2775.

    Article  PubMed  CAS  Google Scholar 

  • European Medicines Agency (2010): European Medicines Agency recommends precautionary recall of batches of clopidogrel-containing medicines from Acino Pharma GmbH. Press Release 25 March 2010. Internet: www.ema.europa.eu/humandocs/PDFs/EPAR/clopidogrel1Apharma/17960610en.pdf

  • Grau E, Tenias JM, Real E, Medrano J, Ferrer R, Pastor E, Selfa S (2001): Home treatment of deep venous thrombosis with low molecular weight heparin: Long-term incidence of recurrent venous thromboembolism. Am J Hematol 67: 10–14.

    Article  PubMed  CAS  Google Scholar 

  • Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB, Moliterno DJ, O’Gara P, Whitlow P; American Heart Association; American College of Cardiology; Society for Cardiovascular Angiography and Interventions; American College of Surgeons; American Dental Association; American College of Physicians (2007): Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 115: 813–818.

    Article  PubMed  Google Scholar 

  • Gum PA, Kottke-Marchant K, Poggio ED et al (2001): Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88: 230–235.

    Article  PubMed  CAS  Google Scholar 

  • Ho PM, Maddox TM, Wang L et al. (2009): Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301: 937–944.

    Article  PubMed  CAS  Google Scholar 

  • Hoots WK, Nugent DJ (2006): Evidence for the benefits of prophylaxis in the management of hemophilia A. Thromb Haemost 96: 433–440.

    PubMed  CAS  Google Scholar 

  • Jneid H, Bhatt DL, Corti R, Badimon JJ, Fuster V, Francis GS (2003): Aspirin and clopidogrel in acute coronary syndromes. Therapeutic insights from the CURE study. Arch Intern Med 163: 1145–1153.

    CAS  Google Scholar 

  • Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, Sudlow C, Henderson R, Hawkins N, Riemsma R (2004): Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation. Health Technol Assess (38): iii-iv, 1–196.

    Google Scholar 

  • Juurlink DN, Gomes T, Ko DT et al (2009): A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 180: 713–718.

    Article  PubMed  Google Scholar 

  • Keng TB (2001): Heparin-induced thrombocytopenia and thrombosis syndrome: in vivo cross-reactivity with danaparoid and successful treatment with r-Hirudin. Br J Haematol 114: 394–396.

    Article  PubMed  CAS  Google Scholar 

  • Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM et al. (1996): Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 334: 682–687.

    Article  PubMed  CAS  Google Scholar 

  • Kwok CS, Loke YK (2010): Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther 31: 810–823.

    PubMed  CAS  Google Scholar 

  • Lensing AWA, Prins MH, Davidson BL, Hirsh J (1995): Treatment of deep venous thrombosis with low-molecular-weight heparins: a meta-analysis. Arch Intern Med 155: 601–607.

    Article  PubMed  CAS  Google Scholar 

  • Levine M, Gent M, Hirsh J, Leclerc J, Anderson D et al. (1996): A comparison of lowmolecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 334: 677–681.

    Article  PubMed  CAS  Google Scholar 

  • Martel N, Lee J, Wells PS (2005): Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a metaanalysis. Blood 106: 2710–2715.

    Article  PubMed  CAS  Google Scholar 

  • Mehta SR, Yusuf S, Peters RJG, Bertrand ME, Lewis BL, Katarajan MK et al. for the Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators (2001): Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients underoing percutaneous coronary intervention: The PCI-CURE study. Lancet 358: 527–533.

    Article  PubMed  CAS  Google Scholar 

  • Mismetti P, Laporte S, Darmon J-Y, Buchmüller A, Decousus H (2001): Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 88: 913–930.

    Article  PubMed  CAS  Google Scholar 

  • Neubauer H, Krüger JC, Lask S, Endres HG, Pepinghege F, Engelhardt A, Bulut D, Mügge A (2009): Comparing the antiplatelet effect of clopidogrel hydrogensulfate and clopidogrel besylate: a crossover study. Clin Res Cardiol 98: 533–540.

    Article  PubMed  CAS  Google Scholar 

  • Park SJ, Park DW, Kim YH et al., (2010): Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 362:1374–1382.

    Article  PubMed  CAS  Google Scholar 

  • Silber S, Borggrefe M, Hasenfuß G et al (2010): Kommentare zu den Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zur Diagnostik und Therapie von Patienten mit ST-Streckenhebungsinfarkt (STEMI). Kardiologie 4: 84–92.

    Article  Google Scholar 

  • Simon T, Verstuyft C, Mary-Krause M et al. (2009): Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360: 363–375.

    Article  PubMed  CAS  Google Scholar 

  • The ACTIVE Investigators (2009): Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 360: 2066–2078.

    Article  Google Scholar 

  • The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (2001): Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without st-segment elevation. N Engl J Med 345: 494–502.

    Article  Google Scholar 

  • The ESPRIT Study Group (2006): Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 367: 1665–1673.

    Article  Google Scholar 

  • The Warfarin Antiplatelet Vascular Evaluation Trial Investigators (2007): Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 357: 217–227.

    Article  Google Scholar 

  • Van de Werf F, Bax J, Betriu A et al. (2008): Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 29: 2909–2945.

    Article  PubMed  Google Scholar 

  • Van der Heijden JF, Hutten BA, Büller HR, Prins MH (2002): Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism (Cochrane Revies). In: The Cochrane Library, Issue 2, 2002. Oxford: Update Software.

    Google Scholar 

  • Walenga JM (2002): Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia. Thromb Res 105: 401–405.

    Article  PubMed  CAS  Google Scholar 

  • White RH, Ginsberg JS (2003): Low-molecular-weight heparins: are thy all the same? Br J Hematol 121: 12–20.

    Article  CAS  Google Scholar 

  • Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators (2007): Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357: 2001–2015.

    Article  PubMed  CAS  Google Scholar 

  • Zed PJ, Tisdale JE, Borzak S (1999): Low-molecular-weight heparins in the management of acute coronary syndromes. Arch Intern Med 159: 1849–1857.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Albert-Ludwig-Universität, Albertstraße 25, 79104, Freiburg

    Prof. Dr. med. Lutz Hein

Authors
  1. Prof. Dr. med. Lutz Hein
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. AOK NORDWEST, Die Gesundheitskasse, Edisonstraße 70, 24145, Kiel

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Hein, L. (2011). Antithrombotika und Antihämorrhagika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2011. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-21992-4_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-21992-4_15

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-21991-7

  • Online ISBN: 978-3-642-21992-4

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation